- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02599922
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
Subjects will be enrolled sequentially in seven dosing groups. Subjects in Groups 1, 2, 3, 4, 5, and 6 will be at least 18 years of age and will receive varying dose levels of study agent. Subjects in Group 4a will be 6 to 17 years of age and will receive the same dose as Group 4. Subjects in Groups 5a and 7 will be between 4 and 8 years of age. Subjects in Group 5a will receive the same dose as Group 5, and subjects in Group 7 will receive the maximum tolerated dose identified in Groups 1, 2, 3, 4, 4a, 5, 5a, and 6.
Safety will be monitored by evaluation of ocular and non-ocular adverse events and hematology and clinical chemistry parameters. Efficacy parameters will include visual acuity, light discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging, functional MRI (fMRI), color brightness test and OCT.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32607
- VitreoRetinal Associates
-
Miami, Florida, United States, 33136
- Bascom Palmer Eye Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60608
- Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts Eye and Ear Infirmary
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Eye Center, Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Cincinnati Eye Institute
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Casey Eye Institute, Oregon Health and Sciences University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria include:
- Male or female subjects with documented mutations in both alleles of the CNGB3 gene;
- Retinal disease consistent with a clinical diagnosis of achromatopsia;
- At least 18 years of age for Groups 1, 2, 3, 4, 5 and 6. At least 6 years of age for Group 4a, and 4-8 years of age for Groups 5a and 7;
- Able to perform tests of visual and retinal function;
- Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent 20/80) based on the average of two examinations at the baseline visit;
- Acceptable laboratory parameters;
- For females of childbearing potential: A negative pregnancy test within 2 days before administration of study agent.
Exclusion Criteria include:
- Best-corrected visual acuity difference between the two eyes of > 15 ETDRS letters (3 lines);
- Evidence of degenerative myopia in the study eye;
- Pre-existing eye conditions that would contribute to vision loss in either eye or increase the risk of subretinal injection in the study eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 2.0 x 10^11 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 2: 4.0 x 10^10 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 3: 1.2 x 10^11 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 4: 3.6 x 10^11 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 4a: 3.6 x 10^11 vg/mL of AGTC-401
Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 5: 1.1 x 10^12 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 5a: 1.1 x 10^12 vg/mL of AGTC-401
Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 6: 3.2 x 10^12 vg/mL of AGTC-401
Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
Experimental: Group 7: MTD of AGTC-401
Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
|
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 1 year
|
Proportion of participants experiencing grade 3 or greater adverse events
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity
Time Frame: 1 year
|
Changes in best corrected visual acuity compared to pre-treatment
|
1 year
|
Light aversion
Time Frame: 1 year
|
Changes in light discomfort testing compared to pre-treatment
|
1 year
|
Color vision
Time Frame: 1 year
|
Changes in color vision testing compared to pre-treatment
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: David Jacobs, MD, MBA, Applied Genetic Technologies Corporation
Publications and helpful links
General Publications
- Davis JL. The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases. Am J Ophthalmol. 2018 Dec;196:xxv-xxix. doi: 10.1016/j.ajo.2018.08.038. Epub 2018 Sep 5.
- Komaromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010 Jul 1;19(13):2581-93. doi: 10.1093/hmg/ddq136. Epub 2010 Apr 8. Erratum In: Hum Mol Genet. 2011 Dec 15;20(24):5024.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGTC_CNGB3-001
- R24EY022023 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achromatopsia
-
Columbia UniversityNot yet recruiting
-
Applied Genetic Technologies CorpActive, not recruitingAchromatopsiaUnited States, Israel
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaCompleted
-
STZ eyetrialLudwig-Maximilians - University of Munich; University Hospital TuebingenActive, not recruiting
-
Applied Genetic Technologies CorpNational Eye Institute (NEI)Completed
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaActive, not recruitingAchromatopsiaUnited Kingdom, United States
-
MeiraGTx UK II LtdJanssen Research & Development, LLCCompleted
-
National Eye Institute (NEI)Completed
-
Foundation Fighting BlindnessRecruitingRetinitis Pigmentosa | Choroideremia | Usher Syndrome | Batten Disease | Leber Congenital Amaurosis | Goldmann-Favre Syndrome | Kearns-Sayre Syndrome | Retinal Disease | Bardet-Biedl Syndrome | Stargardt Disease | Cone Dystrophy | Retinoschisis | Achromatopsia | Gyrate Atrophy | Eye Diseases Hereditary | Bassen-Kornzweig... and other conditionsUnited States
Clinical Trials on rAAV2tYF-PR1.7-hCNGB3
-
Applied Genetic Technologies CorpActive, not recruitingAchromatopsiaUnited States, Israel
-
Beacon TherapeuticsActive, not recruitingX-Linked Retinitis PigmentosaUnited States
-
Beacon TherapeuticsActive, not recruitingX-Linked Retinitis PigmentosaUnited States
-
Applied Genetic Technologies CorpCompletedX-linked RetinoschisisUnited States
-
Beacon TherapeuticsRecruitingX-Linked Retinitis PigmentosaUnited States